Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$21.63 - $57.65 $1.35 Million - $3.6 Million
-62,500 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$11.0 - $28.24 $64,724 - $166,164
-5,884 Reduced 8.6%
62,500 $1.57 Million
Q4 2020

Feb 02, 2021

SELL
$10.12 - $13.94 $13,155 - $18,122
-1,300 Reduced 1.87%
68,384 $821,000
Q3 2020

Nov 05, 2020

BUY
$9.93 - $13.47 $14,895 - $20,205
1,500 Added 2.2%
69,684 $696,000
Q2 2020

Aug 12, 2020

SELL
$9.56 - $12.51 $202,251 - $264,661
-21,156 Reduced 23.68%
68,184 $713,000
Q1 2020

May 12, 2020

BUY
$7.54 - $15.77 $33,176 - $69,388
4,400 Added 5.18%
89,340 $956,000
Q4 2019

Jan 27, 2020

BUY
$7.48 - $17.01 $169,048 - $384,426
22,600 Added 36.25%
84,940 $1.35 Million
Q3 2019

Oct 31, 2019

BUY
$6.89 - $10.45 $64,414 - $97,697
9,349 Added 17.64%
62,340 $489,000
Q2 2019

Aug 15, 2019

BUY
$8.85 - $12.49 $59,215 - $83,570
6,691 Added 14.45%
52,991 $560,000
Q4 2018

Feb 08, 2019

SELL
$8.73 - $13.74 $64,828 - $102,033
-7,426 Reduced 13.82%
46,300 $477,000
Q3 2018

Nov 13, 2018

SELL
$12.7 - $15.79 $43,713 - $54,349
-3,442 Reduced 6.02%
53,726 $703,000
Q2 2018

Aug 15, 2018

SELL
$10.99 - $44.21 $32,222 - $129,623
-2,932 Reduced 4.88%
57,168 $834,000
Q1 2018

May 11, 2018

SELL
$27.95 - $45.04 $81,055 - $130,616
-2,900 Reduced 4.6%
60,100 $2.21 Million
Q4 2017

Feb 06, 2018

BUY
$35.44 - $63.76 $81,512 - $146,648
2,300 Added 3.79%
63,000 $2.36 Million
Q3 2017

Nov 15, 2017

BUY
$53.83 - $67.75 $3.27 Million - $4.11 Million
60,700
60,700 $3.93 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $646M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.